T-cell acute lymphoblastic leukemia (T-ALL) is a challenging clinical entity with high rates of induction failure and relapse. To discover the genetic changes occurring in T-ALL, and those contributing to relapse, we studied zebrafish (Danio rerio) T-ALL samples using array comparative genomic hybridization (aCGH). We performed aCGH on 17 T-ALLs from four zebrafish T-ALL models, and evaluated similarities between fish and humans by comparing all D. rerio genes with copy number aberrations (CNAs) with a cohort of 75 published human T-ALLs analyzed by aCGH. Within all D. rerio CNAs, we identified 893 genes with human homologues and found significant overlap (67%) with the human CNA dataset. In addition, when we restricted our analysis to primary T-ALLs (14 zebrafish and 61 human samples), 10 genes were recurrently altered in 43 zebrafish cancers and X4 human cases, suggesting a conserved role for these loci in T-ALL transformation across species. We also conducted iterative allo-transplantation with three zebrafish malignancies. This technique selects for aggressive disease, resulting in shorter survival times in successive transplant rounds and modeling refractory and relapsed human T-ALL. Fifty-five percent of original CNAs were preserved after serial transplantation, demonstrating clonality between each primary and passaged leukemia. Cancers acquired an average of 34 new CNAs during passaging. Genes in these loci may underlie the enhanced malignant behavior of these neoplasias. We also compared genes from CNAs of passaged zebrafish malignancies with aCGH results from 50 human T-ALL patients who failed induction, relapsed or would eventually relapse. Again, many genes (88/164) were shared by both datasets. Further, nine recurrently altered genes in passaged D. rerio T-ALL were also found in multiple human T-ALL cases. These results suggest that zebrafish and human T-ALLs are similar at the genomic level, and are governed by factors that have persisted throughout evolution.
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Introduction
Genomic alterations are a prominent feature of cancer, and include aneuploidy, chromosomal translocations, and focal amplifications and deletions. Some changes foster oncogenic transformation, whereas others favor the outgrowth of specific subclones in an already established neoplasia (Mullighan et al., 2008) . Gain or loss of certain genes can promote tumor development, metastasis, drug resistance or other clinically pertinent features. Finally, specific genomic changes associated with a particular malignancy type may correlate with prognosis (Armstrong and Look, 2005) . Consequently, the identification of recurrent genomic anomalies contributes to our understanding of cancer.
To detect acquired copy number aberrations (CNAs), array comparative genomic hybridization (aCGH) has been widely applied to human cancers (Pinkel and Albertson, 2005) and is likewise amenable to model organisms (Hodgson et al., 2001; Maydan et al., 2007; Thomas et al., 2007) . Recently, zebrafish (D. rerio) aCGH genomic platforms have become available. An initial D. rerio array contained 286 bacterial artificial chromosome clones enriched for homologous human oncogene and tumor-suppressor sequences, with an approximate 5-Mb resolution . Newer high-density oligonucleotide arrays based on more accurate genomic assemblies (Peterson and Freeman, 2009 ) have even greater resolution.
As vertebrates, zebrafish share most human genes and their functions are conserved. Specifically, D. rerio homologues of human oncogenes and tumor suppressors have preserved actions, making this organism an excellent model to study human cancer (Mione and Trede, 2010) . Supporting this, several transgenic zebrafish lines that mis-express mammalian oncogenes develop near-identical malignancies to humans (Chen et al., 2007; Langenau et al., 2003 Langenau et al., , 2007 Patton et al., 2005; Sabaawy et al., 2006) . Moreover, in studies of zebrafish cancers, CNAs of putative D. rerio oncogenes and tumor suppressors are readily detected .
For zebrafish to be an optimal model to study human cancer, the genes in D. rerio CNAs must be pertinent to human disease. CNAs containing homologous genes from the same tumor type across both species may identify unappreciated players in human neoplasia. To test this hypothesis, we performed aCGH on 17 zebrafish T-ALL samples and compared the results with aCGH findings in human T-ALL (Mullighan et al., 2007 (Mullighan et al., , 2008 Gutierrez et al., 2010a, b) . We concentrated on recurrently altered genes in both human and zebrafish cancers, and those genes shared by leukemias with particularly malignant clinical behavior. Our analyses show a striking overlap between T-ALL CNA genes across species, and support zebrafish as a model to study human leukemogenesis and disease progression.
Results and discussion
We used aCGH to detect somatically acquired CNAs in 17 zebrafish T-ALLs. These represent cancers from four D. rerio genetic models: one transgenic line mis-expressing murine c-Myc (mMyc) (Langenau et al., 2005) and three mutant lines with heritable T-ALL predisposition (hlk, srk, otg) (Frazer et al., 2009 ) (complete sample listing in Supplementary Figure 1) . Genomic DNA of non-malignant tissue from each cancerous fish was used as a hybridization control to eliminate detection of inherited germline copy number variants. T-cell receptor loci on chromosomes 2 and 17 served as internal controls ( Supplementary Figures 2a and 2b) , as deletions occur in these regions during T-cell receptor recombination (Haire et al., 2000; Schorpp et al., 2006; Meeker et al., 2010) . TCR deletions and other CNAs from wild-type D. rerio T cells (pooled from 25 zebrafish) were eliminated from consideration in subsequent analyses, as they are unlikely to be oncogenic (analysis algorithm detailed in Supplementary Methods).
Using two zebrafish aCGH platforms, a total of 840 cancer-specific CNAs were detected, comprised of 335 amplifications and 505 deletions, averaging 49.4 total CNAs per sample (Supplementary Table 1 , Supplementary Figure 3a ). Eight T-ALLs were hybridized to a NimbleGen (Madison, WI, USA) oligonucleotide array; a higher-density Agilent (Santa Clara, CA, USA) array was used for nine other D. rerio samples. Amplifications and deletions averaged 197 and 135 kb, respectively. Depictions of all 17 zebrafish T-ALL genomes and pooled normal T cells are shown in Supplementary  Figures 2 and 4 .
We investigated three D. rerio cancers using a unique approach only possible with an animal model. We iteratively passaged T-ALLs (one leukemia each from srk, hlk, and otg fish) by serial allo-transplantation (examples shown in Supplementary Figure 5) . Our previous studies have found that iterative transplantation of small numbers of cells (1 Â 10 5 ) selects for aggressive disease, with recipient survival times declining in subsequent rounds (Frazer et al., 2009; Rudner et al., 2010; Figure 1a) . We hypothesize that in vivo passaging favors aggressive subclones comprising a minor fraction of the original malignancy. It may also select for new mutations that promote more aggressive disease features. In another zebrafish T-ALL model, individual cells have been shown to act as leukemic stem cells to transmit disease . This approach would eliminate clonal selection and favor the isolation of new mutations. However, because clonal evolution and new mutations are both integral to relapse in human patients (Panzer-Grumayer et al., 2005; Choi et al., 2007; Mullighan et al., 2008) , we opted to impose a 100 000-cell bottleneck. We believe that using small numbers of donor cells can allow both processes to occur, mimicking the clinical scenario of human T-ALL relapse where rare clones repopulate the leukemic pool, as suggested by others (Ren et al., 2009) . 5 cells were transplanted into each recipient. Kaplan-Meier's survival curves for engrafted fish are plotted (first host cohort, n ¼ 11 (red); second cohort, n ¼ 8 (blue); fifth cohort, n ¼ 10 (green); rounds 3 and 4 are not shown for clarity). One fish from each cohort (not plotted) was killed to be the donor for the next transplant series. Recipients had statistically significant differences in mean survival duration for each transplant round (P-values listed in figure) . (b) Partial genomic representations (chromosomes 18-25) of the otg primary T-ALL donor and a fifth passage T-ALL. Results are normalized to non-malignant tissue DNA of the original donor. Red lines depict deletions, green lines reflect amplifications and line lengths correspond to heterozygous vs homozygous deletions. Most CNAs are common to both samples, demonstrating clonality. CNAs gained or lost in fifth passage may reflect selection of a subclone that was a minor population of the original T-ALL and/or new CNA events. Some new CNAs may underlie the more aggressive phenotype of the fifth passage. Graphics created using Nexus5 Copy Number software (BioDiscovery, El Segundo, CA, USA).
Of note, transplantations were into allogeneic, not syngeneic, backgrounds. In our system, T-ALL cells could gain aggressiveness in many ways. Acquiring faster growth or lower apoptosis rates, new cytokine/ stromal independence, enhanced ability to colonize nonlymphoid tissues or improved evasion of host immune responses might all favor higher engraftment and shorter host survival. Although the former properties are pertinent to all human T-ALL, changes in immunogenicity would only be relevant to human cases where transplant is applied therapeutically. To minimize the contribution of immune factors, hosts were irradiated, blunting their responses. Also, because recipients in each round of transplant are genetically distinct from one another, previous hosts and the primary T-ALL, specific host vs T-ALL mismatches are unlikely to persist across multiple transplant iterations. A potential exception could be if cancers deleted their MHC loci, as reported for some human leukemias (Vago et al., 2009) . However, no MHC deletions were seen in our passaged T-ALLs. Nonetheless, we recognize that serial transplantation is only a surrogate for refractory and relapsed human T-ALL.
We compared three 'passaged' T-ALLs with their 'primary' counterparts. In these six cancers, new CNAs were observed that might underlie aggressive clinical behavior (Figure 1b and Supplementary Figure 4) . Overall, serially transplanted T-ALLs had a comparable number of CNAs (62.0 vs 51.3; Supplementary Table 2) . Many CNAs of de novo T-ALLs (55%) were preserved in the passaged counterpart, demonstrating clonality between paired leukemias. Serially transplanted cancers lost 45% of CNAs present in the primary, which may indicate that these were 'passenger' events not necessary for oncogenesis. In addition, this phenomenon suggests the outgrowth of a dominant clone (or clones) lacking some CNAs present in the original. Passaged clones display more aggressive in vivo behavior (Frazer et al., 2009; Rudner et al., 2010; Figure 1a) , and genetic changes in transplant-derived cancers may identify loci responsible for this phenotypic drift. In this study, we detected 101 new CNAs (54% of CNAs from serially transplanted T-ALLs) that are putatively linked to increased aggressiveness.
To explore similarities in genomic instability between D. rerio and human T-ALL, we examined aCGH results from 75 human T-ALL samples obtained from 61 patients. Patients came from three cohorts: Children's Oncology Group Study P9404, n ¼ 40; Dana Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocol 00-01, n ¼ 7; St Jude Cancer Research Hospital patients treated from 1995-2003, n ¼ 14 (Mullighan et al., 2007; Gutierrez et al., 2010a, b) . The St Jude Cancer Research Hospital cohort also contributed aCGH results from the same 14 patients using relapsed samples. In total, these 75 T-ALL samples had 1578 CNAs (mean 24.2/genome), with 510 amplifications and 1068 deletions (Supplementary Table 1 and Supplementary Figure 3b) . The prevalence of CNAs and relative frequency of deletions vs amplifications were similar in human and zebrafish T-ALL (Supplementary Table 1 ). Zebrafish CNAs were smaller and more abundant than in human T-ALLs, but these differences may be derived from inaccuracies in the D. rerio genomic assembly and varying probe densities in the hybridization platform used. It is also notable that the zebrafish genome is not definitively mapped and continues to be refined. Arrays used for these studies were based on either Zv6 (NimbleGen) or Zv8 (Agilent), but a ninth-generation zebrafish genomic build was recently released. Because loci thought to be juxtaposed may actually not be (and truly adjacent loci may not yet be recognized as such), our findings warrant further scrutiny once the D. rerio genome is more completely annotated. Despite this limitation, by concentrating on the specific genes within CNAs, we attempted to identify crucial players in the genomics of T-ALL, irrespective of whether their zebrafish genomic locations are currently accurate.
To compare datasets from these two species, we focused on 'CNA genes' common to human and zebrafish T-ALL. To identify homologous genes shared by both species' CNAs, we first identified all known D. rerio genes located within the 840 CNAs of our 17 zebrafish malignancies. From this list, we excluded genes found on aneuploid chromosomes or other lesions 43 Mb, and from CNAs seen in normal T cells. Overall, 29% (5/17) of D. rerio T-ALLs had at least one trisomy, and two other large amplifications were also excluded (details in Supplementary Methods). This degree of genomic instability was similar to human T-ALLs, where 25% (19/75) were aneuploid. This paring resulted in a list of 943 genes from CNAs of one or more D. rerio T-ALL (Supplementary Table 3 ). We then manually ascertained whether human homologues existed for these 943 genes using online databases and search tools (Supplementary Methods). Over 98% (n ¼ 926) of zebrafish CNA genes had human counterparts, permitting a thorough cross-species comparison and emphasizing the high conservation between these two vertebrates.
We compared this list with CNA genes of the 75 human T-ALLs described above. Of the 926 zebrafish CNA genes, 33 occurred in human germline copy number variants and were not considered (see Supplementary Table 3 ), leaving 893 homologous gene pairs. Of these 893 D. rerio genes, 558 (62.5%) were amplified or deleted in at least one human T-ALL (Table 1) . As human studies used single-nucleotide polymorphism arrays, loss of heterozygosity was also detected in human T-ALLs. With inclusion of human copy-neutral loss of heterozygosity events, even higher overlap was seen between the two datasets (597/893; 66.9%).
Because many human genes were present in at least one T-ALL CNA, the significance of this concordance is diminished. Thus, we focused on genes recurrently altered in both D. rerio and human T-ALL. We compared CNA genes present in 41 zebrafish T-ALL with human homologues seen in CNAs from multiple cases (Table 1) . A total of 253 CNA genes were seen in two or more D. rerio cancers, with 94 of these (37.2%) also occurring in at least two human T-ALLs. Applying these same criteria more stringently, 65 CNA genes were found in X3 zebrafish cancers, with 26/65 (40%) occurring in at least two human T-ALLs and 15/65 (23.1%) in X5 human cases. The intersection of these datasets holds great potential for the discovery of fundamental genes in T-cell malignancy.
In the previous analyses, we identified recurrent CNA genes from primary, passaged and relapsed T-ALL in both species. We further refined our dataset by limiting our analysis to only primary T-ALL. Of 75 human samples, 61 were primary T-ALLs. We compared CNA genes from these cases with our 14 D. rerio primaries. From our 893 analyzable CNA genes, 768 were derived from primary T-ALLs. Of these, 472 (61.5%) occurred in X1 human primary T-ALL CNA (Table 1) . As before, we next concentrated on recurrent CNA genes. Nearly half of these 472 shared CNA genes (218; 46.2%) were seen in multiple human cases (Table 1) . To distinguish the most promising candidates, we identified CNA genes from multiple D. rerio and human primaries. A total of 10 genes were seen in X3 zebrafish and X4 human T-ALLs (complete list in Supplementary  Table 4) . Some of these genes may represent unrecognized oncogenic factors in T-ALL, as their repeated detection in CNAs from divergent species is unlikely to be coincidental. CNAs of these genes were not only recurrent but also focal, further implying that these genes could be oncogenic drivers. Deletions in D. rerio T-ALLs of four of these genes are shown in Figures 2a  and b .
Two of these four genes also had compelling expression patterns in human T-ALL with regard to zebrafish aCGH findings. D. rerio osr2 was deleted in 4 out of 14 zebrafish primary T-ALLs (Figure 2a ) and human OSR2 was seen in CNAs from 6/61 human primaries (Supplementary Table 4 ). Examining OSR2 message levels in 40 human T-ALL primary cancers revealed that 38 (95%) of these shared low OSR2 expression (Supplementary Figure 6) . Likewise, zebrafish tgfbr1b was deleted in 5/14 primaries, with human primary T-ALLs having TGFBR1 CNAs in 6/61 cases. Human T-ALLs generally had low TGFBR1 mRNA levels (30/40; 75%), with only 3 cases (7.5%) showing high expression (Supplementary Figure 6) . We examined whether CNAs of TGFBR1 impacted the outcome (Figure 2c ), but the relatively few cases limited our analysis. A trend towards better overall survival was observed, but was not statistically compelling. One other recurring CNA gene from zebrafish and human T-ALLs, TOR1A, also showed a trend of higher overall survival (Figure 2c ), but did not achieve statistical significance due to low patient numbers. As these CNA genes were identified from primary T-ALLs, no reason existed a priori to expect that they might influence the outcome. Other recurrent CNA genes from primary T-ALLs (Supplementary Table 4 ) also had no prognostic value with respect to patient relapse or survival (data not shown).
TGFBR1 has already been implicated in T-ALL (Remke et al., 2009) . Other genes with established roles in T-ALL (NOTCH1, PHF6, HES1; Weng et al., 2004 Weng et al., , 2006 Van Vlierberghe et al., 2010) were seen in focal CNAs from single zebrafish samples. Additionally, CNAs containing the T-ALL oncogenes LYL1, TAL1, TAL2, HES6, MLL4 and JAK2 were also seen, but were excluded from analysis as they were part of large chromosomal gains. However, despite these shared genomic features, the nine other recurrent CNA genes Abbreviations: CNAs, copy number aberrations; LOH, loss of heterozygosity; T-ALLs, T-cell acute lymphoblastic leukemias.
Shared genomic changes in zebrafish and human T-cell cancer LA Rudner et al in both species (Supplementary Table 4) are not yet recognized as important factors in T-ALL, although they are frequently rearranged in human cases (Mullighan et al., 2007; Remke et al., 2009; Gutierrez et al., 2010a, b) .
Curiously, several known tumor suppressors and oncogenes in human T-ALL, such as CDKN2A, CDKN2B, PTEN, LEF1, WT1 and MYB/AHI1, were not seen in zebrafish. CDKN2A, the gene most often deleted in human T-ALL (Sulong et al., 2009) present in D. rerio, so it was not expected in our aCGH studies. The absence of CDKN2B deletions may allude to differences between species. Of course, genomic rearrangements are only one means to disrupt gene function, and loci absent from CNAs may still be perturbed by other mechanisms. The lack of CNAs involving MYB/AHI1, LEF1, PTEN and WT1 from 17 D. rerio T-ALLs is not statistically compelling, as CNAs of these genes are infrequent in human cases (o12%). Moreover, both PTEN and WT1 are duplicated in trans in the zebrafish genome. This redundancy may obviate their roles as lynchpins in D. rerio T-ALL, as deletion of all four copies of either tumor suppressor is unlikely. Notably, CNAs of PTEN-induced putative kinase 1 (pink1) occurred recurrently in D. rerio (3/17; 17.6%), perhaps representing an alternative mechanism to disrupt Pten function. Finally, two other CNA genes in D. rerio T-ALL, prkca and tfdp1, were not present in the 75 human cases we used for comparison, but CNAs of their homologues have been reported in other human T-ALL datasets (Remke et al., 2009) . As a final comparison, we identified CNA genes from serially passaged zebrafish T-ALL and analyzed them with respect to relapsed human cases. Amplified and deleted genes in passaged, but not primary, T-ALLs may explain transformed cells' acquisition of new aggressive features. Our transplantation model creates highly malignant T-ALLs, with in vivo selection preserving biological constraints absent in cell culture. In this respect, our system mimics aspects of clinical relapse.
We passaged three T-ALLs (1 hlk, 1 srk, 1 otg) until each cancer rapidly engrafted and killed all recipients (on average, host death occurred 14.7 days earlier in the final round: 13.2 vs 27.9 days). Passaged and primary leukemias were then analyzed by aCGH to detect newly acquired CNAs (Figure 1b and Supplementary Figure 4) . These comprised a total of 164 D. rerio genes with human homologues. Remarkably, 9 of the 164 genes occurred in 2 passaged T-ALLs (complete list in Supplementary Table  4) , far more than predicted by chance. Furthermore, eight of the nine genes were not seen in any D. rerio primary T-ALL, suggesting that they may not be oncogenic. Rather, these genes are predicted to enhance malignant progression in our assay, and perhaps worsen outcomes in human patients.
We compared these 164 CNA genes with the human dataset. Because passaged cancers reflect the most aggressive zebrafish T-ALLs, we focused on human cases with the worst outcomes, induction failures and relapses. Cancers in these cases may have CNAs in genes that contribute to their therapeutic failure. Specifically, we evaluated CNA genes in primary T-ALLs of patients who achieved remission but later relapsed (n ¼ 27), relapsed samples themselves (n ¼ 14) and nine patients who failed induction (Table 2 ). In total, these 50 cases had CNAs of 88/164 (53.7%) genes from passaged D. rerio T-ALL. All nine recurring genes from passaged zebrafish T-ALL were also human CNA genes. In fact, all nine genes were still coincident when we restricted our analysis to only the 23 worst cases (14 relapses and 9 induction failures). Moreover, 8/9 genes were in CNAs from multiple bad outcome human T-ALL cases, with 6/9 seen in X5 cases (Supplementary Table 4) . Strikingly, CNAs of these genes were common in relapsed and induction failure cases, but rare in 25 cases with event-free survival (Supplementary Table 4) . Thus, CNAs of these loci correlate strongly with T-ALL treatment failure, and may predict clinical outcome.
To examine this hypothesis further, we examined expression and outcome data for one of these CNA Shared genomic changes in zebrafish and human T-cell cancer LA Rudner et al genes. C7orf60, a gene of unknown function, occurred in CNAs of seven human cases, and six were in the poor outcome subset. The D. rerio homologue of this gene was amplified in two passaged T-ALLs, so this predicted that patients with high C7orf60 transcript levels might fare poorly. Indeed, 20/21 event-free survival cases had low C7orf60, but 6/19 induction failures and cases destined to relapse showed high C7orf60 levels, and the 5 cases with highest C7orf60 mRNA signal all belonged to the poor outcome class (Supplementary Figure 6) . Moreover, despite the paucity of cases, T-ALLs with C7orf60 genomic rearrangements had significantly inferior overall survival (P ¼ 0.02; Figure 2c ). A second recurrent CNA from passaged zebrafish and human T-ALLs (containing the ERGIC1 and FLT4 genes) also displayed inferior outcomes, but fewer cases precluded statistical confidence (P ¼ 0.14; Figure 2c ). These nine genes, encountered repeatedly in CNAs from aggressive disease in both species, may be prognostic factors in human T-ALL. Additionally, CNAs of these loci may not only predict therapeutic failure, but also identify pathways governing poor outcome at the molecular level. Together with the 10 recurring CNA genes shared by primary zebrafish and human T-ALLs, our cross-species comparisons have identified a short list of genes of potential importance to T-cell malignancy. Further testing is needed to interrogate this premise, but our data clearly suggest that critical genetic similarities exist between these species' cancers, and that fundamental properties governing oncogenesis and disease progression have persisted over eons of evolution.
